Overholt Bergein F, Panjehpour Masoud, Halberg Daniel L
Laser Center, Thompson Cancer Survival Center, Knoxville, Tennessee, USA.
Gastrointest Endosc. 2003 Aug;58(2):183-8. doi: 10.1067/mge.2003.327.
Photodynamic therapy has been shown to eliminate Barrett's dysplasia. This report presents long-term follow-up data after photodynamic therapy of Barrett's esophagus with high-grade dysplasia, low-grade dysplasia, or early stage carcinoma.
Porfimer-photodynamic therapy was performed in 103 patients. The Nd:YAG laser was used to photoablate small areas of residual or untreated Barrett's mucosa. Acid suppression was maintained in all patients (omeprazole, 20 mg twice a day).
Mean follow-up was 50.65 (SD 20.57) months (range 2-122 months). For the 82 patients not lost to follow-up, mean follow-up was 58.5 (12.89) months (range 41-132 months). After photodynamic therapy, the length of Barrett's mucosa decreased by a mean of 6.92 cm (range 1-22 cm). Of the 65 patients with high-grade dysplasia, 60 (94%) had elimination of high-grade dysplasia. Three (4.6%) patients developed subsquamous adenocarcinoma. Subsquamous, nondysplastic, metaplastic epithelium was found in 4 patients (4.9%). Strictures occurred in 18% with one session of photodynamic therapy, and 50% with two treatments, 30% overall. For the 103 patients, intention-to-treat success rates were 92.9%, 77.5%, and 44.4% for, respectively, low-grade dysplasia, high-grade dysplasia, and early stage carcinoma groups.
Porfimer-photodynamic therapy with supplemental Nd:YAG photoablation and continuous treatment with omeprazole reduces the length of Barrett's mucosa, eliminates high-grade dysplasia, and, by comparison with historical data, may reduce the expected frequency of carcinoma.
光动力疗法已被证明可消除巴雷特异型增生。本报告展示了对伴有高级别异型增生、低级别异型增生或早期癌的巴雷特食管进行光动力治疗后的长期随访数据。
对103例患者实施了卟吩姆钠光动力治疗。使用钕钇铝石榴石激光对残留或未治疗的小块巴雷特黏膜进行光凝消融。所有患者均维持抑酸治疗(奥美拉唑,每日2次,每次20毫克)。
平均随访时间为50.65(标准差20.57)个月(范围2 - 122个月)。对于82例未失访患者,平均随访时间为58.5(12.89)个月(范围41 - 132个月)。光动力治疗后,巴雷特黏膜长度平均减少6.92厘米(范围1 - 22厘米)。65例高级别异型增生患者中,60例(94%)高级别异型增生消失。3例(4.6%)患者发生黏膜下腺癌。4例(4.9%)患者发现黏膜下、无异型增生的化生上皮。单次光动力治疗后狭窄发生率为18%,两次治疗后为50%,总体发生率为30%。对于103例患者,低级别异型增生组、高级别异型增生组和早期癌组的意向性治疗成功率分别为92.9%、77.5%和44.4%。
卟吩姆钠光动力治疗联合钕钇铝石榴石激光补充光凝消融及奥美拉唑持续治疗可缩短巴雷特黏膜长度,消除高级别异型增生,并且与既往数据相比,可能降低预期的癌变发生率。